Improvement in Ulcerative Colitis by Administration of Benralizumab for Comorbid Refractory Bronchial Asthma: A Novel Clinical Observation | Zendy

Ken Sugimoto | Zendy; Shoya Fujita | Zendy; Takahiro Miyazu | Zendy; Natsuki Ishida | Zendy; Shinya Tani | Zendy; Mihoko Yamade | Zendy; Yasushi Hamaya | Zendy; Moriya Iwaizumi | Zendy; Takahisa Furuta | Zendy; Satoshi Osawa | Zendy

Open Access

Improvement in Ulcerative Colitis by Administration of Benralizumab for Comorbid Refractory Bronchial Asthma: A Novel Clinical Observation

Author(s) -

Ken Sugimoto,

Shoya Fujita,

Takahiro Miyazu,

Natsuki Ishida,

Shinya Tani,

Mihoko Yamade,

Yasushi Hamaya,

Moriya Iwaizumi,

Takahisa Furuta,

Satoshi Osawa

Publication year - 2020

Publication title -

inflammatory bowel diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.932

H-Index - 146

eISSN - 1536-4844

pISSN - 1078-0998

DOI - 10.1093/ibd/izaa225

Subject(s) - benralizumab , ulcerative colitis , medicine , refractory (planetary science) , asthma , immunology , eosinophil , mepolizumab , biology , disease , astrobiology

We present a case of ulcerative colitis improved through benralizumab, which binds to the eosinophil IL-5 receptor and the Fcy receptor on natural killer cells, inducing antibody-dependent cell-mediated cytotoxicity, causing apoptosis, and directly removing eosinophils, in treating comorbid refractory bronchial asthma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research